United Immunity raises ¥2.2bn in equity and debt for immunotherapy programmes
The package comprises ¥1.8bn in private equity and ¥400m in debt, supporting UI-102 and in-vivo CAR-macrophage development.
United Immunity raised ¥2.2 billion in financing, comprising ¥1.8 billion in private equity and ¥400 million in debt.
The company plans to advance global clinical development of UI-102, move its in-vivo CAR-macrophage programme towards clinical development and expand research and development.
UI-102 uses nanoparticles to deliver an immune stimulant to tumour-associated macrophages. The broader platform delivers therapeutic payloads to myeloid cells, including macrophages and dendritic cells.
Use of funds
Advance global clinical development of UI-102
Move in-vivo CAR-macrophage therapy toward clinical development
Expand research and development programs